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Abstract 
Background 
Patients with COVID-19 are thought to be at higher risk of cardiometabolic and pulmonary 
complications, but quantification of that risk is limited. We aimed to describe the overall burden 
of these complications in survivors of severe COVID-19. 
Methods 
Working on behalf of NHS England we used data from the OpenSAFELY platform linking 
primary care records to death certificate and hospital data. We constructed two cohorts: a 
COVID-19 cohort consisting of patients discharged following hospitalisation with COVID-19, and 
a comparison population of patients discharged following hospitalisation with pneumonia in 
2019. Outcomes included DVT, PE, ischaemic stroke, MI, heart failure, AKI and new type 2 
diabetes diagnosis. Outcome rates from hospital discharge were measured in each cohort, 
stratified by patient demographics and 30-day period. We fitted Cox regression models to 
estimate crude and age/sex adjusted hazard ratios comparing outcome rates between the two 
cohorts. 
Results 
Amongst the population of 31,569 patients discharged following hospitalisation with COVID-19, 
the highest rates were observed for heart failure (199.3; 95% CI: 191.8 - 207.1) and AKI (154.5; 
95% CI: 147.9 - 161.4). Rates of DVT, heart failure, ischaemic stroke, MI, PE and diabetes were 
high over the four months post discharge, especially in the first month. Patterns were broadly 
similar to those seen in patients discharged with pneumonia but somewhat higher in the 
COVID-19 population for stroke (adj-HR 1.78; 95% CI: 1.53 - 2.08), PE (adj-HR 1.38; 95% CI: 
1.21 - 1.58), MI (adj-HR 1.46; 95% CI: 1.20 - 1.76), AKI (adj-HR 1.27; 95% CI: 1.19 - 1.36) and 
T2DM (adj-HR 1.28; 95% CI: 1.08 - 1.50). 
Conclusions 
In this descriptive study of survivors of severe COVID-19, rates of the measured outcomes are 
at least as high, though in some cases slightly higher, than in patients discharged after 
hospitalisation with pneumonia. Further work is needed to identify what characteristics of 
COVID-19 patients put them at highest risk of adverse events. 
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Introduction 
Cardiometabolic and pulmonary complications, especially thrombotic events, have been 
described as a key feature of the severe acute phase of COVID-19. A recent systematic review 
estimated the risk of venous thromboembolism (VTE) to be ~15% in hospitalised COVID-19 
patients, with higher risks observed in people admitted to intensive care (~30%​1–3​). Underlying 
reasons for this increased risk are likely to be multifactorial, including immobility following 
illness/hospitalisation as well as the known association with infection in general, mediated 
through interactions with general inflammatory and other immune pathways​4​. The possibility that 
SARS-CoV-2 may directly trigger pulmonary thrombi via vascular damage and inflammatory 
effects in the lung has also been raised ​5​.  
 
As the COVID-19 pandemic has progressed, it is increasingly reported that some patients who 
recover from the acute disease phase go on to experience a range of post-recovery clinical 
problems.  This post-acute COVID-19 syndrome is currently not well described or understood, 
with the UK National Institute for Health and Care Excellence stating that any body system 
could be affected, for an undetermined period of time ​6​. Any such syndrome now needs to be 
defined and quantified so that patients and health services can know what outcomes may be 
expected, and plan accordingly​6,7​. It is also unclear whether COVID-19 is exceptional in its 
association with cardiometabolic events, or comparable to other respiratory pathogens.  
 
Work to date on cardiometabolic outcomes with COVID-19 has largely focused on risks during 
hospitalisation, with a lack of evidence on how these risks evolve in survivors of severe 
COVID-19. We therefore measured the rates of cardiometabolic outcomes in people in England 
with COVID-19, focusing on those who were discharged from hospital following the acute phase 
of COVID-19. For context, we compared these rates with those seen amongst people 
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Methods 
Study design and data sources 
We conducted an observational cohort study using electronic health record (EHR) data from 
primary care practices using The Phoenix Partnership (TPP) software linked to Office for 
National Statistics (ONS) death registrations and Secondary Uses Service (SUS) data 
(containing hospital records) through OpenSAFELY. This is a data analysis platform developed 
during the COVID-19 pandemic, on behalf of NHS England, to allow near real-time analysis of 
pseudonymised primary care records at scale, covering approximately 40% of the population in 
England, operating within the EHR vendor’s highly secure data centre.​8,9​ Details on Information 
Governance for the OpenSAFELY platform can be found in the Appendix.  
Population 
We included all adults aged ≥18 years registered with a general practice for ≥1 year on the 
index date with information on age, sex, and socioeconomic deprivation. From this source 
population we selected two cohorts: all patients hospitalised with COVID-19 in 2020, and a 
comparison cohort containing all patients hospitalised with non-COVID pneumonia across the 
equivalent period in 2019. The COVID-19 and pneumonia cohorts were selected as anyone 
hospitalised with an associated diagnostic code for COVID-19 or pneumonia respectively 
(referred to as the “index hospitalisation”). 
Outcomes and follow-up 
We measured eight outcomes: deep vein thrombosis (DVT), pulmonary embolism (PE), 
ischaemic stroke, myocardial infarction (MI), heart failure, acute kidney injury (AKI) and new 
type 2 diabetes diagnosis.  
 
The study periods ran between 1st February and 1st November in either 2019 or 2020, 
depending on the population (as defined above). The follow-up period began on the discharge 
date of the index COVID-19 or pneumonia hospital stay. For each analysis, follow-up ended on 
the earliest of: the first recorded outcome event, the study end date, or the date of death of the 
patient. For the AKI outcome, we excluded patients who were receiving dialysis before the index 
date (defined as presence of a dialysis code or eGFR < 15ml/min). For diabetes, we excluded 
any patients who had a previous diabetes event, to ensure only incident diagnoses were 
measured. 
 
Outcomes were defined primarily as the presence of a diagnostic code for each of the 
respective outcomes, either in the general practice record, in hospital, or as a cause of death on 
a death certificate. For AKI, the outcome was restricted just to events recorded in hospital or on 
the death certificate. For the primary analysis, we excluded use of a GP record if the patient had 
a recent outcome recorded within three months before the index date (including if they had been 
recorded during the index hospitalisation). This was to prevent double counting of the same 
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event, for example where a GP updates the record of a patient, recording an event that 
occurred during a recent hospitalisation. 
Statistical Methods 
We described the demographics of patients discharged from an admission with COVID-19 and 
pneumonia.  
 
Rates were reported for each outcome, per 10,000 person months, initially for the whole 
follow-up time, then stratified into time windows: 0-29 days, 30-59 days, 60-89 days, 90-120 
days and 120+ days post discharge, to determine how the rate of outcomes changed over time. 
Rates were also stratified by age, sex and ethnicity.  
 
We used Cox regression models to estimate hazard ratios (HRs) and 95% confidence intervals 
(CIs) to compare the rates of each outcome between the hospitalised COVID-19 group and the 
hospitalised pneumonia group. We investigated crude univariable and age and sex adjusted 
models. The same patient can contribute person-time to both exposure groups, however these 
periods are non-overlapping. Theoretically this will lead to narrower confidence intervals, 
therefore we applied robust standard errors.  
 
In sensitivity analyses we tested the effect of including a) previously omitted outcomes recorded 
in the primary care record when there was a recorded outcome within 3 months before the index 
date, and b) only events recorded in hospital or as a cause of death on a death certificate.  
Software and reproducibility 
Data management was performed using the OpenSAFELY software, Python 3.8 and SQL, and 
analysis using Stata 16.1. All codelists alongside code for data management and analyses can 
be found at: ​https://github.com/opensafely/post-covid-thrombosis-research ​. All software for the 
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Results 
We identified 31,569 patients discharged following an admission with COVID-19 and 68,303 
patients discharged with pneumonia in 2019. Demographics for the cohorts studied are 
summarised in Table 1. Compared to the COVID-19 cohort, the pneumonia cohort had a higher 
proportion aged over 70. The ethnic breakdown was broadly similar between the two groups, 
COVID-19 patients had a higher proportion of patients who are Asian and Asian British. 
 
Overall rates of each outcome per 10,000 person months for the whole follow-up are presented 
in Table 2. For the majority of outcomes we observed higher rates of serious cardiometabolic 
and pulmonary complications in discharged COVID-19 patients compared to discharged 
pneumonia patients (Table 2, Figure 1). For both cohorts, the largest absolute rates were for 
AKI and heart failure. Overall rates stratified by age, sex and ethnicity are present in the 
appendix (Tables A5-A12). For COVID-19 patients, rates of stroke, heart failure MI and AKI 
were consistently higher amongst the over 80s, although the pattern of results was not 
consistent across other ages groups. Similarly, rates were not constant by ethnic group, for 
example, the rate of new T2DM diagnoses were slightly higher amongst black patients 
discharged following an admission with COVID-19. 
 
Stratified overall rates in 30-day time windows are shown in Figure 1. For discharged COVID-19 
patients we observed the highest rates for all outcomes in the first 30 days post-discharge, with 
a gradual decline in subsequent periods. This was remarkably consistent with the pattern of 
rates observed for patients discharged with pneumonia in 2019. For both cohorts, we observed 
pronounced rates of AKI and heart failure in the first 30 days post-discharge (Figure 1). 
 
Cox regression models were used to estimate HRs comparing the hazards of each outcome 
between the discharged COVID-19 and pneumonia groups (Table 3, Figure 2).  After age and 
sex adjustment, we observed an increased risk in the majority of outcomes for discharged 
COVID-19 patients compared to discharged pneumonia patients. We observed modest 
increases in risks for stroke (HR 1.78; 95% CI: 1.53 - 2.08), PE (HR 1.38; 95% CI: 1.21 - 1.58), 
MI (HR 1.46; 95% CI: 1.20 - 1.76),  AKI (HR 1.27; 95% CI: 1.19 - 1.36) and T2DM (HR 1.28; 
95% CI: 1.08 - 1.50). 
 
Results from a sensitivity analysis investigating robustness of absolute and relative rates to 
outcome definition are presented in the Appendix. Change in outcome definitions did not 
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Table 1: Patient demographics amongst patients discharged with COVID-19 in 2020 and all 







  Pneumonia (2019) 
Discharged 
  COVID-19 
Total 68,303 31,569 
Age    
18 - 49 8,277 (12.1) 6,427 (20.4) 
50 - 59 7,153 (10.5) 4,910 (15.6) 
60 - 69 11,190 (16.4) 5,208 (16.5) 
70 -79 17,818 (26.1) 6,347 (20.1) 
80 + 23,865 (34.9) 8,677 (27.5) 
Sex   
Male 34,485 (50.5) 14,944 (47.3) 
Female 33,818 (49.5) 16,625 (52.7) 
Ethnicity   
White 45,647 (66.8) 19,353 (62.1) 
Mixed 273 (0.4) 306  (1.0) 
Asian /Asian British 2,670 (3.9) 3,285 (10.4) 
Black 687 (1.0) 1,040 (3.3) 
Other 429 (0.6) 521 (1.6) 
Unknown 18,597 (27.2) 7,073 (22.4) 
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Table 2: Overall rates of outcomes amongst patients discharged with COVID-19 in 2020 and all 













events Rate (95% CI) 
Stroke Discharged COVID-19 13.7 535 39.1 (35.9-42.6) 
 Discharged Pneumonia 31.4 634 20.2 (18.7-21.8) 
DVT Discharged COVID-19 13.7 256 18.7 (16.5-21.1) 
 Discharged Pneumonia 31.4 530 16.9 (15.5-18.4) 
PE Discharged COVID-19 13.6 515 37.8 (34.7-41.2) 
 Discharged Pneumonia 31.3 793 25.3 (23.6-27.1) 
Heart Failure Discharged COVID-19 13.1 2607 199.3 (191.8-207.1) 
 Discharged Pneumonia 29.2 6958 238.7 (233.1-244.3) 
MI Discharged COVID-19 13.7 294 21.4 (19.1-24.0) 
 Discharged Pneumonia 31.4 534 17.0 (15.6-18.5) 
AKI Discharged COVID-19 13 2012 154.5 (147.9-161.4) 
 Discharged Pneumonia 29.8 3933 131.8 (127.7-136.0) 
T2DM Discharged COVID-19 9.3 291 31.2 (27.8-35.0) 
  Discharged Pneumonia 22.3 627 28.1 (26.0-30.4) 
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Table 3: Estimated hazard ratios from univariable and age and sex adjusted Cox regression 
models comparing the risk of outcomes in patients who were discharged with COVID-19 























HR (95% CI) 
Stroke 13.7 535 31.4 634 1.92 (1.71-2.15) 1.78 (1.53-2.08) 
DVT 13.7 256 31.4 530 1.10 (0.95-1.28) 1.06 (0.88-1.28) 
PE 13.6 515 31.3 793 1.50 (1.34-1.68) 1.38 (1.21-1.58) 
Heart failure 13.1 2607 29.2 6958 0.84 (0.81-0.88) 0.98 (0.93-1.05) 
MI 13.7 294 31.4 534 1.26 (1.09-1.46) 1.46 (1.20-1.76) 
AKI 13 2012 29.8 3933 1.17 (1.11-1.24) 1.27 (1.19-1.36) 
T2DM 9.3 291 22.3 627 1.13 (0.98-1.30) 1.28 (1.08-1.50) 
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Figure 1: Rate of outcomes (events per 10,000 person months) in time periods following 
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Figure 2: Hazard ratios for risk of outcomes in patients who were hospitalised with COVID-19 
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Discussion 
Key findings 
In this descriptive study, we set out to report the overall rates of outcomes in each of the 
cohorts, regardless of their cause. We found that the rate of cardiometabolic and pulmonary 
complications following discharge from hospitalisation with COVID-19 followed a broadly similar 
pattern of elevated rates to those discharged from hospital after pneumonia in 2019. Some 
outcomes, such as stroke, PE, AKI and T2DM showed a modestly higher rate in discharged 
COVID-19 patients than discharged pneumonia patients, while the other outcomes we 
measured were not measurably different. The pattern of change in the rate of outcomes over 
time following discharge from hospital was also broadly similar between the COVID-19 and 
pneumonia patients, with a high rate in the initial 30 days of follow-up, then a 2-3 fold drop in the 
next 30 days, followed by a more gradual decline. In both cohorts discharged after 
hospitalisation, rates remained substantial even after more than 120 days. 
Strengths and limitations 
We were able to source our cohorts from the OpenSAFELY platform, which contains over 17m 
adults. This gave us a population of patients who were discharged following hospitalisation with 
COVID-19 of 31,569, allowing us to obtain precise estimates of the rate of each outcome. We 
were also able to draw on multiple linked data sources, including primary care records, 
hospitalisations and death certificates. This allows a more complete picture to be presented of 
the clinical activity surrounding each outcome. 
We believe that our use of an active control population of patients hospitalised with pneumonia 
in 2019 provides useful context for the rates of these outcomes in COVID-19 patients who 
survive hospitalisation. A comparison cohort could also have been attained by matching patients 
from the general population on various attributes such as age, sex and comorbidities. However, 
such a cohort would be lacking the exposure of an acute respiratory illness event requiring 
hospitalisation. We think presenting the rates in this context is more informative than within a 
general population. 
We note that our study aimed to describe clinical events that occurred ​after​ discharge from 
hospital, and therefore may not reflect the true additional morbidity burden of COVID-19 
hospitalisation: specifically we did not set out to describe events that occurred ​during​ hospital 
admission with COVID-19 or pneumonia. However, in our view reliable analysis of in-hospital 
events may only be achievable with bespoke collections of detailed hospital data, due to 
shortcomings in routinely collected administrative data that are widely used for such analyses. 
For example, SUS and HES data contain a list of diagnostic codes associated with each 
hospitalisation, but they do not contain sufficient information to determine the exact timing of all 
events within each hospitalisation episode. This means that time-to event analyses are not 
possible. Furthermore it is not possible in SUS or HES to reliably determine the sequence of 
events during the hospitalisation: so a patient hospitalised with COVID-19, who later had a 
stroke, may be coded in a similar way to a patient who was hospitalised with a stroke, and then 
infected with SARS-CoV-2 while in hospital. In addition, routine PCR testing on hospitalised 
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patients during the pandemic may lead to very high ascertainment of infection with 
SARS-CoV-2, which may not have occurred to the same extent in the comparison population for 
pneumonia admissions. 
We did not attempt to determine here whether any observed differences were due to a particular 
feature of the pathophysiology associated with SARS-CoV-2 infection, or whether other factors 
might have had a greater influence, such as competing risk of death, pre-existing patient 
comorbidities, changes in healthcare provision during the pandemic or differing likelihood of 
ascertainment of pre-existing conditions. In the context of the rapidly changing pandemic, we 
aimed to provide an overview of the rates of outcomes after discharge from hospitalisation with 
COVID-19, compared with pneumonia, to inform health services. 
It has been reported that there was a marked reduction in hospital activity during the first wave 
of the pandemic, for example a 40% reduction in admissions for acute coronary syndrome ​10​. 
This may be in part explained by a reluctance of patients to present at hospitals for fear of 
contracting the virus. As a result, we believe population-level rates of many outcomes will be 
under-ascertained during 2020 compared with 2019. It is unknown whether this applies in the 
same way to patients who have already had severe COVID-19; if ascertainment is lower, then 
this would result in a possible under-estimate of outcome events associated with COVID-19 in 
our study. 
Findings in context 
A recent observational study measured similar outcome events in a population of patients 
discharged from hospital following COVID-19 ​11​. They observed elevated rates in the COVID-19 
population compared to a matched general population control group. Our findings are consistent 
in showing high increased rates of outcomes in patients post-discharge with COVID-19. 
However, importantly we show that these increased rates of outcomes are broadly comparable, 
if not slightly lower, in people discharged from hospital following pneumonia, selected as a 
major non-COVID respiratory infection. 
The impact of the post COVID-19 hospitalisation events described in this study upon the NHS in 
England is substantial. Though the absolute number of events is lower than in the post 
pneumonia hospitalisation cohort, it is likely that the COVID-19 related events will continue to 
make up a substantial proportion of the total hospitalisations for these conditions for some time. 
Future work will also investigate any association between non-hospitalised SARS-CoV-2 
infection and these outcomes, and quantify any likely population level impact.  
Summary 
The rate of cardiometabolic and pulmonary events in COVID-19 survivors discharged from 
hospitalisation was elevated in a similar manner to patients discharged from hospitalisation with 
pre-pandemic pneumonia, with some outcomes observed to have a slightly higher rate in the 
COVID-19 survivors population. Next steps include seeing whether patients at highest risk of 
post-covid outcomes can be identified and determining whether higher risk groups could be 
early targeted for possible preventative action.  
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Figure A1: As Figure 1 but including all GP outcomes rather than censoring if the patient had an 
outcome within the 3 months before index date. AKI and diabetes are unchanged from figure 1. 
 
 
Figure A2: As Figure 1, but without using GP as an outcome (only hospitalisations and death 





 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)




Figure A3: As Figure 2, but outcomes recorded in GP records are not censored if the patient 
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Table A1: As Table 2, but outcomes recorded in GP records are not censored if the patient had 










events Rate (95% CI) 
Stroke Discharged COVID-19 13.6 617 45.2 (41.8-48.9) 
 Discharged Pneumonia 31.3 787 25.1 (23.4-26.9) 
DVT Discharged COVID-19 13.7 286 20.9 (18.6-23.5) 
 Discharged Pneumonia 31.4 578 18.4 (17.0-20.0) 
PE Discharged COVID-19 13.6 665 49.1 (45.5-52.9) 
 Discharged Pneumonia 31.2 1143 36.7 (34.6-38.8) 
Heart Failure Discharged COVID-19 13 2742 210.4 (202.7-218.4) 
 Discharged Pneumonia 28.8 7745 268.6 (262.7-274.6) 
MI Discharged COVID-19 13.7 336 24.5 (22.0-27.3) 
 Discharged Pneumonia 31.3 730 23.3 (21.7-25.0) 
AKI Discharged COVID-19 13 2012 154.5 (147.9-161.4) 
 Discharged Pneumonia 29.8 3933 131.8 (127.7-136.0) 
T2DM Discharged COVID-19 9.3 291 31.2 (27.8-35.0) 
  Discharged Pneumonia 22.3 627 28.1 (26.0-30.4) 
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events Rate (95% CI) 
Stroke Discharged COVID-19 13.7 473 34.5 (31.5-37.8) 
 Discharged Pneumonia 31.4 500 15.9 (14.6-17.4) 
DVT Discharged COVID-19 13.7 186 13.6 (11.7-15.7) 
 Discharged Pneumonia 31.5 370 11.8 (10.6-13.0) 
PE Discharged COVID-19 13.6 450 33.0 (30.1-36.2) 
 Discharged Pneumonia 31.4 690 22.0 (20.4-23.7) 
Heart Failure Discharged COVID-19 13.1 2482 189.2 (181.9-196.8) 
 Discharged Pneumonia 29.3 6408 218.4 (213.2-223.9) 
MI Discharged COVID-19 13.7 265 19.3 (17.1-21.8) 
 Discharged Pneumonia 31.5 466 14.8 (13.5-16.2) 
AKI Discharged COVID-19 13 2012 154.5 (147.9-161.4) 
 Discharged Pneumonia 29.8 3933 131.8 (127.7-136.0) 
T2DM Discharged COVID-19 9.3 291 31.2 (27.8-35.0) 
  Discharged Pneumonia 22.3 627 28.1 (26.0-30.4) 
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Stroke 13.7 473 31.4 500 2.16 (1.90-2.45) 1.98 (1.67-2.36) 
DVT 13.7 186 31.5 370 1.14 (0.96-1.37) 1.07 (0.86-1.32) 
PE 13.6 450 31.4 690 1.51 (1.34-1.70) 1.40 (1.21-1.61) 
Heart 
Failure 13.1 2482 29.3 6408 0.87 (0.83-0.92) 1.02 (0.96-1.09) 
MI 13.7 265 31.5 466 1.29 (1.11-1.50) 1.47 (1.20-1.79) 
AKI 13 2012 29.8 3933 1.17 (1.11-1.24) 1.27 (1.19-1.36) 
T2DM 9.3 291 22.3 627 1.13 (0.98-1.30) 1.28 (1.08-1.50) 
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Table A4: As Table 3, but outcomes recorded in GP records are not censored if the patient had 
























HR (95% CI) 
Stroke 13.6 617 31.3 787 1.78 (1.60-1.98) 1.73 (1.50-1.99) 
DVT 13.7 286 31.4 578 1.12 (0.97-1.30) 1.07 (0.90-1.27) 
PE 13.6 665 31.2 1143 1.34 (1.21-1.47) 1.22 (1.09-1.37) 
Heart 
Failure 13 2742 28.8 7745 0.79 (0.76-0.83) 0.93 (0.88-0.99) 
MI 13.7 336 31.3 730 1.05 (0.92-1.19) 1.20 (1.01-1.42) 
AKI 13 2012 29.8 3933 1.17 (1.11-1.24) 1.27 (1.19-1.36) 
T2DM 9.3 291 22.3 627 1.13 (0.98-1.30) 1.28 (1.08-1.50) 
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Table A5: Rates of stroke amongst patients discharged with COVID-19 in 2020 and all patients 
discharged with non-COVID pneumonia in 2019 stratified by age, sex and ethnicity.  
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Rate (95% CI) 
Overall - 
Discharged COVID-19 13.7 535 39.1 (35.9-42.6) 
Discharged Pneumonia 31.4 634 20.2 (18.7-21.8) 
Age 
18 -49 
Discharged COVID-19 2.9 25 8.6 (5.8-12.8) 
Discharged Pneumonia 3.9 40 10.4 (7.6-14.1) 
50-59 
Discharged COVID-19 2.3 34 14.6 (10.4-20.4) 
Discharged Pneumonia 3.4 41 12.2 (8.9-16.5) 
60-69 
Discharged COVID-19 2.3 68 29.0 (22.9-36.8) 
Discharged Pneumonia 5.2 93 17.8 (14.5-21.8) 
70-79 
Discharged COVID-19 2.7 128 47.2 (39.7-56.2) 
Discharged Pneumonia 8.2 184 22.3 (19.3-25.8) 
80+ 
Discharged COVID-19 3.4 280 82.3 (73.2-92.5) 
Discharged Pneumonia 10.7 276 25.8 (23.0-29.1) 
Sex 
Female 
Discharged COVID-19 6.4 243 37.8 (33.3-42.8) 
Discharged Pneumonia 16 272 17.0 (15.1-19.2) 
Male 
Discharged COVID-19 7.2 292 40.3 (35.9-45.2) 
Discharged Pneumonia 15.4 362 23.4 (21.2-26.0) 
Ethnicity 
White 
Discharged COVID-19 8.3 354 42.5 (38.3-47.2) 
Discharged Pneumonia 20.9 417 19.9 (18.1-21.9) 
Mixed 
Discharged COVID-19 0.1 <5 20.2 (6.5-62.5) 
Discharged Pneumonia 0.1 <5 39.7 (16.5-95.5) 
Asian/Asian 
British 
Discharged COVID-19 1.4 40 29.5 (21.6-40.2) 
Discharged Pneumonia 1.3 18 14.1 (8.9-22.4) 
Black 
Discharged COVID-19 0.5 14 26.7 (15.8-45.2) 
Discharged Pneumonia 0.3 14 44.6 (26.4-75.3) 
Other 
Discharged COVID-19 0.3 <5 3.9 (0.5-27.7) 
Discharged Pneumonia 0.2 <5 24.8 (10.3-59.5) 
Unknown 
Discharged COVID-19 3.1 123 40.0 (33.5-47.7) 
Discharged Pneumonia 8.5 175 20.5 (17.7-23.8) 
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Table A6: Rates of DVT amongst patients discharged with COVID-19 in 2020 and all patients 
discharged with non-COVID pneumonia in 2019 stratified by age, sex and ethnicity.  
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events Rate (95% CI) 
Overall - 
Discharged COVID-19 13.7 256 18.7 (16.5-21.1) 
Discharged Pneumonia 31.4 530 16.9 (15.5-18.4) 
Age 
18 -49 
Discharged COVID-19 2.9 43 14.9 (11.0-20.1) 
Discharged Pneumonia 3.9 77 20.0 (16.0-25.0) 
50-59 
Discharged COVID-19 2.3 28 12.0 (8.3-17.4) 
Discharged Pneumonia 3.4 61 18.1 (14.1-23.3) 
60-69 
Discharged COVID-19 2.3 43 18.3 (13.6-24.7) 
Discharged Pneumonia 5.2 82 15.7 (12.6-19.5) 
70-79 
Discharged COVID-19 2.7 66 24.3 (19.1-31.0) 
Discharged Pneumonia 8.3 122 14.8 (12.4-17.6) 
80+ 
Discharged COVID-19 3.4 76 22.3 (17.8-27.9) 
Discharged Pneumonia 10.7 188 17.6 (15.2-20.3) 
Sex 
Female 
Discharged COVID-19 6.4 117 18.2 (15.2-21.8) 
Discharged Pneumonia 16 285 17.9 (15.9-20.1) 
Male 
Discharged COVID-19 7.3 139 19.2 (16.2-22.6) 
Discharged Pneumonia 15.5 245 15.8 (14.0-18.0) 
Ethnicity 
White 
Discharged COVID-19 8.3 169 20.3 (17.4-23.6) 
Discharged Pneumonia 21 359 17.1 (15.4-19.0) 
Mixed 
Discharged COVID-19 0.1 6 40.8 (18.3-90.9) 
Discharged Pneumonia 0.1 <5 7.9 (1.1-55.9) 
Asian/Asian 
British 
Discharged COVID-19 1.4 12 8.8 (5.0-15.5) 
Discharged Pneumonia 1.3 11 8.6 (4.8-15.5) 
Black 
Discharged COVID-19 0.5 6 11.5 (5.1-25.5) 
Discharged Pneumonia 0.3 9 28.7 (14.9-55.2) 
Other 
Discharged COVID-19 0.3 <5 3.9 (0.5-27.7) 
Discharged Pneumonia 0.2 <5 4.9 (0.7-35.0) 
Unknown 
Discharged COVID-19 3.1 62 20.2 (15.7-25.9) 
Discharged Pneumonia 8.5 149 17.4 (14.8-20.5) 
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Table A7: Rates of PE amongst patients discharged with COVID-19 in 2020 and all patients 
discharged with non-COVID pneumonia in 2019 stratified by age, sex and ethnicity.  
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events Rate (95% CI) 
Overall - 
Discharged COVID-19 13.6 515 37.8 (34.7-41.2) 
Discharged Pneumonia 31.3 793 25.3 (23.6-27.1) 
Age 
18 -49 
Discharged COVID-19 2.9 71 24.7 (19.5-31.1) 
Discharged Pneumonia 3.8 114 29.7 (24.7-35.7) 
50-59 
Discharged COVID-19 2.3 82 35.5 (28.6-44.1) 
Discharged Pneumonia 3.4 89 26.5 (21.6-32.7) 
60-69 
Discharged COVID-19 2.3 101 43.4 (35.7-52.8) 
Discharged Pneumonia 5.2 158 30.3 (26.0-35.5) 
70-79 
Discharged COVID-19 2.7 117 43.3 (36.1-51.9) 
Discharged Pneumonia 8.2 225 27.4 (24.0-31.2) 
80+ 
Discharged COVID-19 3.4 144 42.3 (35.9-49.8) 
Discharged Pneumonia 10.7 207 19.3 (16.9-22.2) 
Sex 
Female 
Discharged COVID-19 6.4 227 35.4 (31.1-40.3) 
Discharged Pneumonia 15.9 408 25.7 (23.3-28.3) 
Male 
Discharged COVID-19 7.2 288 39.9 (35.6-44.8) 
Discharged Pneumonia 15.4 385 25.0 (22.6-27.6) 
Ethnicity 
White 
Discharged COVID-19 8.3 321 38.7 (34.7-43.2) 
Discharged Pneumonia 20.9 523 25.0 (23.0-27.3) 
Mixed 
Discharged COVID-19 0.1 <5 20.3 (6.5-62.8) 
Discharged Pneumonia 0.1 <5 23.8 (7.7-73.7) 
Asian/Asian 
British 
Discharged COVID-19 1.4 47 34.7 (26.1-46.2) 
Discharged Pneumonia 1.3 16 12.5 (7.7-20.4) 
Black 
Discharged COVID-19 0.5 19 36.6 (23.4-57.4) 
Discharged Pneumonia 0.3 16 51.6 (31.6-84.2) 
Other 
Discharged COVID-19 0.3 8 31.5 (15.8-63.0) 
Discharged Pneumonia 0.2 <5 14.8 (4.8-45.9) 
Unknown 
Discharged COVID-19 3.1 117 38.3 (31.9-45.9) 
Discharged Pneumonia 8.5 232 27.3 (24.0-31.0) 
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Table A8: Rates of heart failure amongst patients discharged with COVID-19 in 2020 and all 
patients discharged with non-COVID pneumonia in 2019 stratified by age, sex and ethnicity.  
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events Rate (95% CI) 
Overall - 
Discharged COVID-19 13.1 2607 199.3 (191.8-207.1) 
Discharged Pneumonia 29.2 6958 238.7 (233.1-244.3) 
Age 
18 -49 
Discharged COVID-19 2.9 75 26.0 (20.7-32.6) 
Discharged Pneumonia 3.8 187 49.0 (42.5-56.6) 
50-59 
Discharged COVID-19 2.3 146 63.6 (54.1-74.8) 
Discharged Pneumonia 3.3 322 98.6 (88.4-110.0) 
60-69 
Discharged COVID-19 2.3 317 140.1 (125.5-156.4) 
Discharged Pneumonia 4.9 911 184.2 (172.6-196.5) 
70-79 
Discharged COVID-19 2.5 694 273.4 (253.8-294.5) 
Discharged Pneumonia 7.6 2031 267.9 (256.5-279.8) 
80+ 
Discharged COVID-19 3.1 1375 443.4 (420.5-467.4) 
Discharged Pneumonia 9.5 3507 367.4 (355.4-379.7) 
Sex 
Female 
Discharged COVID-19 6.2 1191 193.3 (182.6-204.6) 
Discharged Pneumonia 14.8 3384 227.9 (220.4-235.7) 
Male 
Discharged COVID-19 6.9 1416 204.7 (194.3-215.6) 
Discharged Pneumonia 14.3 3574 249.8 (241.7-258.1) 
Ethnicity 
White 
Discharged COVID-19 7.9 1757 222.0 (211.8-232.6) 
Discharged Pneumonia 19.5 4540 233.0 (226.3-239.8) 
Mixed 
Discharged COVID-19 0.1 10 68.8 (37.0-127.9) 
Discharged Pneumonia 0.1 29 244.6 (170.0-351.9) 
Asian/Asian 
British 
Discharged COVID-19 1.3 148 111.9 (95.2-131.4) 
Discharged Pneumonia 1.2 329 282.1 (253.2-314.3) 
Black 
Discharged COVID-19 0.5 47 91.9 (69.0-122.3) 
Discharged Pneumonia 0.3 63 214.8 (167.8-275.0) 
Other 
Discharged COVID-19 0.3 16 63.5 (38.9-103.7) 
Discharged Pneumonia 0.2 49 261.6 (197.7-346.1) 
Unknown 
Discharged COVID-19 2.9 629 214.4 (198.3-231.9) 
Discharged Pneumonia 7.9 1948 246.6 (235.9-257.8) 
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Table A9: Rates of MI amongst patients discharged with COVID-19 in 2020 and all patients 
discharged with non-COVID pneumonia in 2019 stratified by age, sex and ethnicity.  
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events Rate (95% CI) 
Overall - 
Discharged COVID-19 13.7 294 21.4 (19.1-24.0) 
Discharged Pneumonia 31.4 534 17.0 (15.6-18.5) 
Age 
18 -49 
Discharged COVID-19 2.9 9 3.1 (1.6-6.0) 
Discharged Pneumonia 3.9 18 4.6 (2.9-7.4) 
50-59 
Discharged COVID-19 2.3 28 12.0 (8.3-17.4) 
Discharged Pneumonia 3.4 29 8.6 (6.0-12.3) 
60-69 
Discharged COVID-19 2.3 40 17.0 (12.5-23.2) 
Discharged Pneumonia 5.2 96 18.3 (15.0-22.4) 
70-79 
Discharged COVID-19 2.7 78 28.7 (23.0-35.8) 
Discharged Pneumonia 8.2 163 19.8 (17.0-23.0) 
80+ 
Discharged COVID-19 3.4 139 40.7 (34.5-48.1) 
Discharged Pneumonia 10.7 228 21.3 (18.7-24.3) 
Sex 
Female 
Discharged COVID-19 6.5 120 18.6 (15.5-22.2) 
Discharged Pneumonia 16 222 13.9 (12.2-15.8) 
Male 
Discharged COVID-19 7.3 174 24.0 (20.6-27.8) 
Discharged Pneumonia 15.5 312 20.2 (18.1-22.6) 
Ethnicity 
White 
Discharged COVID-19 8.4 178 21.3 (18.4-24.7) 
Discharged Pneumonia 21 362 17.3 (15.6-19.1) 
Mixed 
Discharged COVID-19 0.1 <5 33.9 (14.1-81.5) 
Discharged Pneumonia 0.1 <5 7.9 (1.1-55.8) 
Asian/Asian 
British 
Discharged COVID-19 1.4 25 18.4 (12.4-27.2) 
Discharged Pneumonia 1.3 25 19.6 (13.2-29.0) 
Black 
Discharged COVID-19 0.5 <5 9.5 (4.0-22.8) 
Discharged Pneumonia 0.3 <5 12.7 (4.8-33.7) 
Other 
Discharged COVID-19 0.3 <5 15.7 (5.9-41.8) 
Discharged Pneumonia 0.2 <5 4.9 (0.7-35.1) 
Unknown 
Discharged COVID-19 3.1 77 25.0 (20.0-31.3) 
Discharged Pneumonia 8.6 141 16.5 (14.0-19.4) 
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Table A10: Rates of AKI amongst patients discharged with COVID-19 in 2020 and all patients 
discharged with non-COVID pneumonia in 2019 stratified by age, sex and ethnicity.  
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events Rate (95% CI) 
Overall - 
Discharged COVID-19 13 2012 154.5 (147.9-161.4) 
Discharged Pneumonia 29.8 3933 131.8 (127.7-136.0) 
Age 
18 -49 
Discharged COVID-19 2.8 130 45.8 (38.5-54.4) 
Discharged Pneumonia 3.8 239 63.7 (56.1-72.3) 
50-59 
Discharged COVID-19 2.2 160 71.1 (60.9-83.1) 
Discharged Pneumonia 3.2 265 81.8 (72.5-92.2) 
60-69 
Discharged COVID-19 2.2 303 136.3 (121.8-152.6) 
Discharged Pneumonia 5 547 109.6 (100.8-119.1) 
70-79 
Discharged COVID-19 2.5 514 203.0 (186.2-221.3) 
Discharged Pneumonia 7.8 1156 148.6 (140.3-157.4) 
80+ 
Discharged COVID-19 3.2 905 284.4 (266.5-303.6) 
Discharged Pneumonia 10.1 1726 171.3 (163.4-179.6) 
Sex 
Female 
Discharged COVID-19 6.2 863 139.8 (130.8-149.4) 
Discharged Pneumonia 15.3 1848 121.1 (115.7-126.7) 
Male 
Discharged COVID-19 6.9 1149 167.7 (158.3-177.7) 
Discharged Pneumonia 14.6 2085 143.0 (137.0-149.3) 
Ethnicity 
White 
Discharged COVID-19 7.9 1327 167.4 (158.6-176.6) 
Discharged Pneumonia 20 2575 128.9 (124.0-133.9) 
Mixed 
Discharged COVID-19 0.1 6 41.0 (18.4-91.3) 
Discharged Pneumonia 0.1 17 144.0 (89.5-231.6) 
Asian/Asian 
British 
Discharged COVID-19 1.3 114 87.3 (72.7-104.9) 
Discharged Pneumonia 1.2 176 149.9 (129.3-173.7) 
Black 
Discharged COVID-19 0.5 53 108.6 (83.0-142.2) 
Discharged Pneumonia 0.3 39 134.1 (98.0-183.6) 
Other 
Discharged COVID-19 0.2 8 32.1 (16.0-64.2) 
Discharged Pneumonia 0.2 25 134.7 (91.0-199.3) 
Unknown 
Discharged COVID-19 2.9 504 173.4 (158.9-189.2) 
Discharged Pneumonia 8.1 1101 136.1 (128.3-144.4) 
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Table A11: Rates of T2DM amongst patients discharged with COVID-19 in 2020 and all patients 
discharged with non-COVID pneumonia in 2019 stratified by age, sex and ethnicity.  
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events Rate (95% CI) 
Overall - 
Discharged COVID-19 9.3 291 31.2 (27.8-35.0) 
Discharged Pneumonia 22.3 627 28.1 (26.0-30.4) 
Age 
18 -49 
Discharged COVID-19 2.4 49 20.3 (15.3-26.8) 
Discharged Pneumonia 3.4 57 16.7 (12.8-21.6) 
50-59 
Discharged COVID-19 1.6 55 33.7 (25.9-43.9) 
Discharged Pneumonia 2.6 64 24.8 (19.4-31.6) 
60-69 
Discharged COVID-19 1.5 59 40.6 (31.5-52.5) 
Discharged Pneumonia 3.5 130 36.7 (30.9-43.6) 
70-79 
Discharged COVID-19 1.6 54 33.0 (25.3-43.1) 
Discharged Pneumonia 5.4 191 35.1 (30.5-40.5) 
80+ 
Discharged COVID-19 2.2 74 33.8 (26.9-42.5) 
Discharged Pneumonia 7.3 185 25.2 (21.9-29.2) 
Sex 
Female 
Discharged COVID-19 4.6 134 29.3 (24.7-34.7) 
Discharged Pneumonia 11.7 303 25.8 (23.1-28.9) 
Male 
Discharged COVID-19 4.8 157 33.0 (28.3-38.6) 
Discharged Pneumonia 10.6 324 30.6 (27.5-34.1) 
Ethnicity 
White 
Discharged COVID-19 5.9 180 30.7 (26.5-35.5) 
Discharged Pneumonia 15.1 403 26.7 (24.2-29.5) 
Mixed 
Discharged COVID-19 0.1 0 0.0 (0.0-0.0) 
Discharged Pneumonia 0.1 <5 38.4 (12.4-119.0) 
Asian/Asian 
British 
Discharged COVID-19 0.7 25 34.9 (23.6-51.7) 
Discharged Pneumonia 0.6 37 67.0 (48.5-92.5) 
Black 
Discharged COVID-19 0.3 17 60.5 (37.6-97.3) 
Discharged Pneumonia 0.2 <5 21.9 (8.2-58.2) 
Other 
Discharged COVID-19 0.2 <5 30.2 (12.6-72.7) 
Discharged Pneumonia 0.1 <5 17.3 (4.3-69.4) 
Unknown 
Discharged COVID-19 2.2 64 29.2 (22.8-37.3) 
Discharged Pneumonia 6.3 178 28.2 (24.4-32.7) 
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Information governance and ethics 
NHS England is the data controller; TPP is the data processor; and the key researchers on 
OpenSAFELY are acting on behalf of NHS England. OpenSAFELY is hosted within the TPP 
environment which is accredited to the ISO 27001 information security standard and is NHS IG 
Toolkit compliant;​12,13​ patient data are pseudonymised for analysis and linkage using industry 
standard cryptographic hashing techniques; all pseudonymised datasets transmitted for linkage 
onto OpenSAFELY are encrypted; access to the platform is via a virtual private network (VPN) 
connection, restricted to a small group of researchers who hold contracts with NHS England and 
only access the platform to initiate database queries and statistical models. Pseudonymised 
structured data include demographics, medications prescribed from primary care, diagnoses, 
and laboratory measures. No free text data are included. All database activity is logged; only 
aggregate statistical outputs leave the platform environment following best practice for 
anonymisation of results such as statistical disclosure control for low cell counts.​14​ The 
OpenSAFELY research platform adheres to the obligations of the UK General Data Protection 
Regulation (GDPR) and the Data Protection Act 2018. In March 2020, the Secretary of State for 
Health and Social Care used powers under the UK Health Service (Control of Patient 
Information) Regulations 2002 (COPI) to require organisations to process confidential patient 
information for the purposes of protecting public health, providing healthcare services to the 
public and monitoring and managing the COVID-19 outbreak and incidents of exposure;  this 
sets aside the requirement for patient consent.​15​ Taken together, these provide the legal bases 
to link patient datasets on the OpenSAFELY platform. GP practices, from which the primary 
care data are obtained, are required to share relevant health information to support the public 
health response to the pandemic, and have been informed of the OpenSAFELY analytics 
platform. This study was approved by the Health Research Authority (REC reference 
20/LO/0651) and by the LSHTM Ethics Board (ref 21863). 
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